Jul 24, 2026 07:51AM
Jul 23, 2026 04:06PM
Jul 23, 2026 04:05PM
Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Jul 22, 2026 06:30AM
Jul 22, 2026 06:30AM Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Jul 16, 2026 08:00AM
Jul 14, 2026 07:00AM
Jul 14, 2026 07:00AM
Jun 9, 2026 04:47PM
Jun 9, 2026 04:47PM
Jun 4, 2026 04:30PM
Jun 1, 2026 02:53AM Summit's ivonescimab shows survival benefit in lung cancer trial
May 31, 2026 09:06AM
May 30, 2026 08:00AM
May 14, 2026 09:15AM
May 4, 2026 07:32AM
Apr 30, 2026 04:32PM
Mar 27, 2026 08:16AM
Mar 27, 2026 08:15AM Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Mar 16, 2026 12:50AM
Feb 26, 2026 06:45PM
Feb 25, 2026 06:38AM
Feb 23, 2026 04:05PM
Feb 17, 2026 05:05PM
Feb 2, 2026 06:50AM
Jan 30, 2026 04:30PM Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 30, 2026 05:41AM
Jan 29, 2026 07:30AM
Jan 29, 2026 07:30AM
Jan 12, 2026 06:15AM
Jan 12, 2026 06:15AM
Jan 12, 2026 06:01AM
Jan 12, 2026 06:00AM Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NS
Jan 9, 2026 08:16PM
Jan 6, 2026 07:30AM
Dec 5, 2025 04:30PM
Nov 7, 2025 09:02AM
Nov 7, 2025 09:00AM
Nov 4, 2025 07:00AM
Oct 31, 2025 07:00AM Summit to present ivonescimab lung cancer trial results at SITC 2025
Oct 31, 2025 07:00AM
Oct 22, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 20, 2025 07:37AM
Oct 20, 2025 06:45AM
Oct 20, 2025 06:45AM
Oct 19, 2025 10:30AM Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the
Oct 17, 2025 07:00AM

326,431 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All